PURPOSE: Xerostomia is a debilitating side effect of radiotherapy in patients with head and neck cancer. We undertook a prospective study of the effect on xerostomia and outcomes of sparing one or both parotid glands during radiotherapy for patients with squamous cell carcinoma of the head and neck. METHODS AND MATERIALS: Patients with locally advanced squamous cell carcinoma of the head and neck received definitive (70 Gy in 2 Gy fractions) or adjuvant (60-66 Gy in 2 Gy fractions) curative-intent radiotherapy using helical tomotherapy with concurrent chemotherapy if appropriate. Group A received < 26 Gy to the left and right parotids and group B received < 26 Gy to either parotid. RESULTS: The study included 126 patients; 114 (55 in group A and 59 in group B) had follow-up data. There were no statistically significant differences between groups in disease stage. Xerostomia was significantly reduced in group A vs. group B (p = 0.0381). Patients in group A also had significantly less dysphagia. Relapse-free and overall survival were not compromised in group A: 2-year relapse-free survival was 86% vs. 72% in group B (p = 0.361); 2-year overall survival was 88% and 76%, respectively (p = 0.251). CONCLUSION: This analysis suggests that reducing radiotherapy doses to both parotid glands to < 26 Gy can reduce xerostomia and dysphagia significantly without compromising survival. Sparing both parotids while maintaining target volume coverage and clinical outcome should be the treatment goal and reporting radiotherapy doses delivered to the individual parotids should be standard practice.
PURPOSE:Xerostomia is a debilitating side effect of radiotherapy in patients with head and neck cancer. We undertook a prospective study of the effect on xerostomia and outcomes of sparing one or both parotid glands during radiotherapy for patients with squamous cell carcinoma of the head and neck. METHODS AND MATERIALS: Patients with locally advanced squamous cell carcinoma of the head and neck received definitive (70 Gy in 2 Gy fractions) or adjuvant (60-66 Gy in 2 Gy fractions) curative-intent radiotherapy using helical tomotherapy with concurrent chemotherapy if appropriate. Group A received < 26 Gy to the left and right parotids and group B received < 26 Gy to either parotid. RESULTS: The study included 126 patients; 114 (55 in group A and 59 in group B) had follow-up data. There were no statistically significant differences between groups in disease stage. Xerostomia was significantly reduced in group A vs. group B (p = 0.0381). Patients in group A also had significantly less dysphagia. Relapse-free and overall survival were not compromised in group A: 2-year relapse-free survival was 86% vs. 72% in group B (p = 0.361); 2-year overall survival was 88% and 76%, respectively (p = 0.251). CONCLUSION: This analysis suggests that reducing radiotherapy doses to both parotid glands to < 26 Gy can reduce xerostomia and dysphagia significantly without compromising survival. Sparing both parotids while maintaining target volume coverage and clinical outcome should be the treatment goal and reporting radiotherapy doses delivered to the individual parotids should be standard practice.
Authors: Judith M Roesink; Maria Schipper; Wim Busschers; Cornelis P J Raaijmakers; Chris H J Terhaard Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-20 Impact factor: 7.038
Authors: Drew C Brotherston; Ian Poon; Tuyen Le; Martin Leung; Alex Kiss; Jolie Ringash; Judith Balogh; Justin Lee; James R Wright Journal: Head Neck Date: 2012-03-20 Impact factor: 3.147
Authors: Silke Tribius; Anna S Ihloff; Thorsten Rieckmann; Cordula Petersen; Markus Hoffmann Journal: Cancer Lett Date: 2011-03-04 Impact factor: 8.679
Authors: P García-Peris; L Parón; C Velasco; C de la Cuerda; M Camblor; I Bretón; H Herencia; J Verdaguer; C Navarro; P Clave Journal: Clin Nutr Date: 2007-10-22 Impact factor: 7.324
Authors: Marije R Vergeer; Patricia A H Doornaert; Derek H F Rietveld; C René Leemans; Ben J Slotman; Johannes A Langendijk Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-26 Impact factor: 7.038
Authors: Hendrik Andreas Wolff; Friedrich Ihler; Nina Zeller; Christian Welz; Klaus Jung; Martin Canis; Wolfgang Steiner Journal: Eur Arch Otorhinolaryngol Date: 2015-04-12 Impact factor: 2.503
Authors: Valerio Nardone; Paolo Tini; Christophe Nioche; Maria Antonietta Mazzei; Tommaso Carfagno; Giuseppe Battaglia; Pierpaolo Pastina; Roberta Grassi; Lucio Sebaste; Luigi Pirtoli Journal: Radiol Med Date: 2018-01-24 Impact factor: 3.469
Authors: K Eom; E K Chie; K Kim; J J Jang; S W Kim; D Y Oh; S A Im; T Y Kim; Y J Bang; S W Ha Journal: Strahlenther Onkol Date: 2013-08-03 Impact factor: 3.621
Authors: K M J van Gestel; D J M Buurman; R Pijls; P A W H Kessler; P L A van den Ende; A L Hoffmann; E G C Troost Journal: Strahlenther Onkol Date: 2013-08-22 Impact factor: 3.621